Gerding DN, et al. - Researchers performed this post hoc analysis of pooled monocolonal antibodies for Clostridium difficile therapy (MODIFY) I/II data, to assess the bezlotoxumab efficacy in participants with characteristics associated with increased risk for C. difficile infection (CDI) recurrence (rCDI). The modified intent-to-treat population who received bezlotoxumab or placebo (n = 1554) by risk factors for rCDI that were prespecified in the statistical analysis plan was analyzed: age ≥65 years, history of CDI, compromised immunity, severe CDI, and ribotype 027/078/244. In this work, these risk factors are identified as appropriate to recognize patients at high risk for rCDI. While bezlotoxumab induced the greatest reduction of rCDI among participants with ≥3 risk factors, it may also benefit those with 1 or 2 risk factors.